Sanovas is a life‑science holding company that develops and commercializes next‑generation micro‑invasive diagnostics, devices, and drug‑delivery technologies through spin‑off companies. The company focuses on miniaturized tools for minimally invasive surgery (M‑I‑S), enabling diagnosis and therapeutic interventions in spaces as small as one millimeter in diameter. Sanovas has originated over 100 multinational patents and plans to commercialize its technologies across specialties including oncology, pulmonology, cardiology, neurosurgery, ENT, GI, urology, and gynecology via partnerships and spin‑outs. It has established partnerships including a joint venture with the Mayo Clinic and collaborations with physicians affiliated with Harvard Medical School. Financially, Sanovas has raised more than $30 million to fund operations, about two‑thirds of which came from a pioneering “social finance” model conceived by CEO Larry Gerrans. That model uses investment proceeds derived from self‑directed IRAs and is documented in a UC Berkeley Fung Institute case study. Sanovas intends to diversify assets across multiple companies as part of its spin‑out strategy to accelerate development and commercialization.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2015